INSERM

Acticor Biotech Receives European Medicines Agency (EMA) Endorsement on Key Parameters of ACTISAVE, Its Pivotal Phase II/III Study for Registration in Stroke

Retrieved on: 
Monday, December 5, 2022
Health, Research, Pharmaceutical, Science, Cardiology, Biotechnology, Newton, Stroke, Document, Standard of care, CHMP, Intracerebral hemorrhage, Medicine, MAA, Mab, Agency, Centre de documentation de la musique contemporaine, EMA, Patient, Disability, Death, Infarction, ESOC, Regulatory affairs, ISIN, Biotechnology, Rankine scale, Committee, Particle-size distribution, GPVI, European Medicines Agency, Medication, AIS, PRIME, Clinical trial, Safety, A&B, Brain, Mortality, Marketing, VI, Thrombectomy, Committee for Medicinal Products for Human Use, Pharmaceutical industry, Medical imaging, INSERM

The discussion meeting took place remotely in October 2022, and Acticor Biotech provided a list of questions concerning the non-clinical development and the study design of the ACTISAVE study.

Key Points: 
  • The discussion meeting took place remotely in October 2022, and Acticor Biotech provided a list of questions concerning the non-clinical development and the study design of the ACTISAVE study.
  • Although CHMP recommendations were issued to further detail some analyses, the statistical methodology was therefore endorsed on its general principles.
  • In July 2022, Acticor Biotech was granted "PRIME" status by the European Medicines Agency (EMA) for glenzocimab in the treatment of stroke.
  • The forward-looking statements contained in this press release are also subject to risks not yet known to Acticor Biotech or not currently considered material by Acticor Biotech.

Acticor Biotech: World’s First Clinical Trial to Test New Drug Glenzocimab for Heart Attacks

Retrieved on: 
Tuesday, November 22, 2022
Health, Research, Pharmaceutical, Science, Cardiology, Biotechnology, Newton, Clinical trial, CTU, Brain, Survival, University, Centre de documentation de la musique contemporaine, European Medicines Agency, Infarction, STEMI, University Hospitals Birmingham NHS Foundation Trust, Stroke, A&B, BHP, Blood, Medicine, ISIN, Queen Elizabeth Hospital, Degenerative disease, Partnership, Myocardial infarction, ESOC, Mortality, Intracerebral hemorrhage, Clinical trials unit, MI, University of Birmingham, EMA, Document, Angioplasty, Queen Elizabeth Hospital Birmingham (1933–2010), Thrombosis, GPVI, Therapy, Mab, Hospital, Sri Jayadeva Institute of Cardiovascular Sciences and Research, Northern General Hospital, VI, Associate, Heart, Patient, Medical device, Pharmaceutical industry, INSERM, Cardiology

Partnership between the University of Birmingham and Acticor Biotech (Paris:ALACT) will see patients with heart attacks treated with glenzocimab, a promising new class of drug for the first time.

Key Points: 
  • Partnership between the University of Birmingham and Acticor Biotech (Paris:ALACT) will see patients with heart attacks treated with glenzocimab, a promising new class of drug for the first time.
  • A potential new drug to improve the long-term outcomes for heart attack patients will be trialled in the UK.
  • Although immediate opening of the blocked coronary artery by angioplasty in cases of heart attack is now routine, significant heart damage still occurs.
  • Were delighted to work with Acticor to see whether this new class of drug has the potential to improve the outcomes of our patients with heart attacks.

EnChroma Supports Colourblind Students at RWTH Aachen University

Retrieved on: 
Tuesday, November 22, 2022
General Health, Health, University, Optical, Education, Economic development, Student, SBIR, University of California, Davis, Tourism, Parent, University of Hamburg, Tibbetts Award, Alfred University, North Carolina State University, Library, Medical research, Multimedia, Small business, Garden, Common, Woman, RWTH Aachen University, Museum, RWTH, Pennsylvania State University, CVD, NIH, Severe cognitive impairment, Faculty, University, INSERM, Learning, Perception, School, Bay, Boston University, Medicine, Cosmetics, EnChroma

VORSCHUB at RWTH Aachen University today announced that colourblind students and staff will now be able to borrow EnChroma colourblind glasses on campus to help them overcome the obstacles to learning and everyday life that colour vision deficiency (CVD) poses.

Key Points: 
  • VORSCHUB at RWTH Aachen University today announced that colourblind students and staff will now be able to borrow EnChroma colourblind glasses on campus to help them overcome the obstacles to learning and everyday life that colour vision deficiency (CVD) poses.
  • With over 47,000 students, and nearly 10,000 faculty and staff, an estimated 2,400 people at RWTH Aachen University are color blind.
  • VORSCHUB at RWTH Aachen University joins the University of Hamburg as the first European universities to align with numerous prestigious universities in the US in supporting the needs of colour blind students via the EnChroma Colour Accessibility Programme .
  • This Program is already helping colour blind students at Boston University, North Carolina State University, Penn State University, Alfred University and others.

ImCheck Presents Initial Patient Data from the EVICTION-2 Clinical Trial at SITC Annual Meeting

Retrieved on: 
Friday, November 11, 2022
Olive, CNRS, Clinical trial, Lung, NKS, T, Melanoma, SITC, INSERM, Society for Immunotherapy of Cancer, Granulocyte, Society, Cancer, MD, NK, Pembrolizumab, Therapy, Immunotherapy, CD8, Prostate, Doctor of Philosophy, Neoplasm, Degenerative disease, Research, Part, Patient, Annual general meeting, AACR, EMSO, Infection, Malignancy, Hematological Cancer Research Investment and Education Act, Antibody, Natural killer T cell, Colorectal cancer, LD, Immunology, Vaccine, Pharmaceutical industry, Butyrophilin, subfamily 1, member A1

The safety profile for the combination exhibited no dose-limiting toxicities in the first 3 dose cohorts and tolerability remained consistent without any new or increased adverse reactions.

Key Points: 
  • The safety profile for the combination exhibited no dose-limiting toxicities in the first 3 dose cohorts and tolerability remained consistent without any new or increased adverse reactions.
  • EVICTION-2 is a first-in-human, dose escalation (Part 1) and cohort expansion (Part 2) clinical trial evaluating ICT01 in combination with low dose subcutaneous IL-2.
  • BTN3A is essential for the activation of the anti-tumor immune response of 92 T cells.
  • ImCheck Therapeutics is designing and developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel super-family of immunomodulators.

Cytovia Therapeutics Presents New Data on TALEN® Gene-Edited iNK Cells and GPC3-Targeted Flex-NK™ Bispecific Antibodies at 2022 SITC Annual Meeting

Retrieved on: 
Monday, November 7, 2022
TKI, Lymphatic system, Society for Immunotherapy of Cancer, Research, Hepatitis B, ADCP, CDC, Multimedia, Lead, Glioblastoma, American Cancer Society, Risk, Death, NASH, Cell, Liver cancer, Incidence, Non-alcoholic fatty liver disease, Cellectis, NK, IPSC, HCC, Fatty liver disease, Therapy, Cornerstone, Hepatocellular carcinoma, Immunotherapy, TALEN, Life expectancy, Ink, Survival rate, Monoclonal antibody, Cancer, National, Partnership, NAFLD, Disease, Technology, INSERM, Survival, Diagnosis, Laboratory, Patient, Society, SITC, National Cancer Institute, UCSF, Vaccine, NCR1

The data will be presented at the Society for Immunotherapy of Cancer's 37thAnnual Meeting (SITC 2022) taking place inBoston, MA, and virtuallyNovember 8-12th, 2022.

Key Points: 
  • The data will be presented at the Society for Immunotherapy of Cancer's 37thAnnual Meeting (SITC 2022) taking place inBoston, MA, and virtuallyNovember 8-12th, 2022.
  • "Additionally, we have now generated TALEN gene-edited iNK cells and demonstrated enhanced antitumor activity.
  • The data shows that iNK cells edited with an IL-15 knock-in and TGFR2 knock-out result in enhanced antitumor activity.
  • The company is developing three types of iPSC-derived NK (or iNK) cells: unedited iNK cells, TALEN gene-edited iNK cells with improved function and persistence, and TALEN gene-edited iNK cells with chimeric antigen receptors (CAR-iNKs) to improve tumor-specific targeting.

Kura Oncology Reports Third Quarter 2022 Financial Results

Retrieved on: 
Thursday, November 3, 2022
Bristol Myers Squibb, Society, FDA, Large-cell lung carcinoma, Research, National Institute, U.S. Securities and Exchange Commission, INSERM, Program, Company, GLOBE, KMT2A, IND, Breakthrough, Mutation, ASH, FTI, HRAS, Tipifarnib, ID, Security (finance), NPM1, Patient, Cancer, HNSCC, Breakthrough therapy, EGFR, Webcast, Neoplasm, Medicine, Head, Data, KURA, Therapy, III, Investment, Safety, NSCLC, Nasdaq, Organization, PIK3CA, Risk, News, AML, Achievement, EORTC, Bank, Pharmaceutical industry, Lithium

ET

Key Points: 
  • ET
    SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported third quarter 2022 financial results and provided a corporate update.
  • Research and development expenses for the third quarter of 2022 were $25.0 million, compared to $22.4 million for the third quarter of 2021.
  • General and administrative expenses for the third quarter of 2022 were $11.6 million, compared to $11.3 million for the third quarter of 2021.
  • ET / 5:00 a.m. PT today, November 3, 2022, to discuss the financial results for the third quarter 2022 and to provide a corporate update.

Quantum Genomics Announces Lack of Significant Efficacy for Firibastat in Their Phase III Study, FRESH and is Redirecting to New Developments

Retrieved on: 
Friday, October 28, 2022
Company, LinkedIn, Heart failure, Growth, FRESH, CNRS, National Research Council Canada, Brain, Genomics, CEO, INSERM, III, Paris Descartes University, Patient, Euronext Growth, Cardiology, AHA, Research, GLOBE, Twitter, Medical research, Congress, Hypertension, Pharmaceutical industry

"Firibastat has unfortunately failed to demonstrate significantly greater efficacy than placebo in the phase III study FRESH.

Key Points: 
  • "Firibastat has unfortunately failed to demonstrate significantly greater efficacy than placebo in the phase III study FRESH.
  • This has caused the Company to prematurely discontinue the second phase III study, REFRESH, for ethical reasons concerning the patients.
  • For the same reason, in view of these results, it has been decided to stop the development of firibastat in cardiovascular," added Bruno Besse, Medical Director of Quantum Genomics.
  • Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain.

Cytovia Therapeutics To Present New Data on CD38 Flex-NK™ Cell Engager Bispecific Antibodies for Multiple Myeloma at 2022 ASH Annual Meeting

Retrieved on: 
Thursday, October 27, 2022
UCSF, Protein, Hepatocellular carcinoma, HCC, Bone marrow, Hematology, Ink, Natural killer T cell, American Society of Hematology, INSERM, Glioblastoma, Lymphatic system, Immunotherapy, CTCL, Cornerstone, Technology, Therapy, Patient, TALEN, Skin, National Cancer Institute, Partnership, CAR, CD38, BCMA, Research, NK, Society, Multiple myeloma, Multimedia, ASH, Cellectis, Cancer, National, B cell, Daratumumab, Transplant, Survival, Laboratory, Death, Standard of care, World Cancer Research Fund UK, Safety, Vaccine, NCR1

Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster II

Key Points: 
  • Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster II
    Multiple Myeloma is a currently incurable cancer, affecting a type of white blood cell known as plasma cells.
  • It leads to an accumulation of tumor cells in the bone marrow, rapidly outnumbering healthy blood cells.
  • Cytovia Therapeutics aims to accelerate patient access to transformational cell therapies and immunotherapies, addressing several of the most challenging unmet medical needs in cancer.
  • Cytovia has developed a strategic partnership with CytoLynx Therapeutics focused on research and development, manufacturing, and commercialization activities inGreater Chinaand beyond.

Coave Therapeutics Strengthens Board of Directors

Retrieved on: 
Thursday, October 20, 2022
National Institute, LinkedIn, Master of Science, Therapy, List of life sciences, Growth, General manager, Science, Neurodegeneration, Medical research, Biotechnology, Takeda Pharmaceutical Company, RNA interference, INSEAD, MBA, Research, The Advisory Board Company, Bachelor of Science, Senior, Eye, University, Company, Doctor of Philosophy, AAV, Industry, INSERM, Board, CEO, Portfolio strategy, Safety, ATyr Pharma, Management, Molecular biology, Consulate General of Israel to the Pacific Northwest Region, Board of directors, Director, International Management Institute, New Delhi, Genzyme, Central nervous system, Pharmaceutical industry, Vaccine, University of Paris, Astellas Pharma, Physics

PARIS, Oct. 20, 2022 /PRNewswire/ -- Coave Therapeutics ('Coave'), a biotech company leading the transition of genetic medicine from (ultra) rare to prevalent conditions in neurodegenerative diseases, today announces Frederic Chereau as Chairman of the Board and the appointment of Dr Claudia Mitchell, PhD, MBA to the Company's Board of Directors as an independent non-executive director.

Key Points: 
  • PARIS, Oct. 20, 2022 /PRNewswire/ -- Coave Therapeutics ('Coave'), a biotech company leading the transition of genetic medicine from (ultra) rare to prevalent conditions in neurodegenerative diseases, today announces Frederic Chereau as Chairman of the Board and the appointment of Dr Claudia Mitchell, PhD, MBA to the Company's Board of Directors as an independent non-executive director.
  • Dr Claudia Mitchell added: "I am delighted to be joining Coave's Board during this exciting period of growth for the Company.
  • The Coave Board of Directors is as follows:
    At Coave Therapeutics, we are leading the transition of genetic medicine from (ultra) rare to prevalent conditions, with an initial focus on neurodegenerative diseases.
  • Headquartered in Paris, France, Coave Therapeutics is backed by leading international life sciences investors.

Coave Therapeutics Strengthens Board of Directors

Retrieved on: 
Thursday, October 20, 2022
National Institute, LinkedIn, Master of Science, Therapy, List of life sciences, Growth, General manager, Science, Neurodegeneration, Medical research, Biotechnology, Takeda Pharmaceutical Company, RNA interference, INSEAD, MBA, Research, The Advisory Board Company, Bachelor of Science, Senior, Eye, University, Company, Doctor of Philosophy, AAV, Industry, INSERM, Board, CEO, Portfolio strategy, Safety, ATyr Pharma, Management, Molecular biology, Consulate General of Israel to the Pacific Northwest Region, Board of directors, Director, International Management Institute, New Delhi, Genzyme, Central nervous system, Pharmaceutical industry, Vaccine, University of Paris, Astellas Pharma, Physics

PARIS, Oct. 20, 2022 /PRNewswire/ -- Coave Therapeutics ('Coave'), a biotech company leading the transition of genetic medicine from (ultra) rare to prevalent conditions in neurodegenerative diseases, today announces Frederic Chereau as Chairman of the Board and the appointment of Dr Claudia Mitchell, PhD, MBA to the Company's Board of Directors as an independent non-executive director.

Key Points: 
  • PARIS, Oct. 20, 2022 /PRNewswire/ -- Coave Therapeutics ('Coave'), a biotech company leading the transition of genetic medicine from (ultra) rare to prevalent conditions in neurodegenerative diseases, today announces Frederic Chereau as Chairman of the Board and the appointment of Dr Claudia Mitchell, PhD, MBA to the Company's Board of Directors as an independent non-executive director.
  • Dr Claudia Mitchell added: "I am delighted to be joining Coave's Board during this exciting period of growth for the Company.
  • The Coave Board of Directors is as follows:
    At Coave Therapeutics, we are leading the transition of genetic medicine from (ultra) rare to prevalent conditions, with an initial focus on neurodegenerative diseases.
  • Headquartered in Paris, France, Coave Therapeutics is backed by leading international life sciences investors.